These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7695468)

  • 21. New NO-donors with antithrombotic and vasodilating activities, V: Oligonitroso sydnone imines.
    Rehse K; Schleifer KJ; Martens A; Kämpfe M
    Arch Pharm (Weinheim); 1994 Jun; 327(6):393-7. PubMed ID: 8048846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New NO-donors with antithrombotic and vasodilating activities, Part 16. 3-Amino-1,2,4-oxadiazol-5-ones as prodrugs for hydroxyguanidines.
    Rehse K; Bade S
    Arch Pharm (Weinheim); 1996 Dec; 329(12):535-40. PubMed ID: 9038421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New NO donors with antithrombotic and vasodilating activities, Part 24. Hydrazine derivatives.
    Rehse K; Shahrouri T
    Arch Pharm (Weinheim); 1998 Oct; 331(10):308-12. PubMed ID: 9844577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NO donors with antithrombotic and vasodilating activities, Part 23. Organic azides.
    Satyanarayana K; Rehse K
    Arch Pharm (Weinheim); 1998 Jun; 331(6):207-10. PubMed ID: 9713253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New NO-donors with antithrombotic and vasodilating activities, Part 19. Pseudonitroles and their dimeric azodioxides.
    Rehse K; Herpel M
    Arch Pharm (Weinheim); 1998 Feb; 331(2):79-84. PubMed ID: 9525092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-Substituted imidazo[1,2-d][1,2,4]-thiadiazoles: a novel class of factor XIIIa inhibitors.
    Leung-Toung R; Tam TF; Wodzinska JM; Zhao Y; Lowrie J; Simpson CD; Karimian K; Spino M
    J Med Chem; 2005 Apr; 48(7):2266-9. PubMed ID: 15801818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New NO-donors with antithrombotic and vasodilating activities, Part 17. Arylazoamidoximes and 3-arylazo-1,2,4-oxadiazol-5-ones.
    Rehse K; Bade S; Harsdorf A; Clement B
    Arch Pharm (Weinheim); 1997 Dec; 330(12):392-8. PubMed ID: 9474899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiaggregating and antithrombotic activities of new 1, 2, 3-triazolecarboxamides.
    Cwiklicki A; Rehse K
    Arch Pharm (Weinheim); 2004 Mar; 337(3):156-63. PubMed ID: 15038061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New NO donors with antithrombotic and vasodilating activities, Part 26. Amidoximes and their prodrugs.
    Rehse K; Brehme F
    Arch Pharm (Weinheim); 1998 Dec; 331(12):375-9. PubMed ID: 9923191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New no-donors with antithrombotic and vasodilating activities, X: Antiplatelet and antithrombotic effects of 3-methylsydnone-5-nitrosimine (RE 2047) in combination with ASA, pentoxifylline, and ticlopidine.
    Rehse K; Ciborski T
    Arch Pharm (Weinheim); 1995 Jan; 328(1):71-8. PubMed ID: 7695475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, antiplatelet and vasorelaxing activities of xanthone derivatives.
    Lin KW; Fang SC; Hung CF; Shieh BJ; Yang SC; Teng CM; Lin CN
    Arch Pharm (Weinheim); 2009 Jan; 342(1):19-26. PubMed ID: 19035386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Furazanobenzofuroxan, furazanobenzothiadiazole, and their N-oxides. A new class of vasodilator drugs.
    Ghosh PB; Everitt BJ
    J Med Chem; 1974 Feb; 17(2):203-6. PubMed ID: 4809256
    [No Abstract]   [Full Text] [Related]  

  • 33. Arylazoamidoximes and related compounds as NO-modulators.
    Schröder A; Kotthaus J; Schade D; Clement B; Rehse K
    Arch Pharm (Weinheim); 2010 Jan; 343(1):9-16. PubMed ID: 19921683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New oxadiazole derivatives showing partly antiplatelet, antithrombotic and serotonin antagonistic properties.
    Bethge K; Pertz HH; Rehse K
    Arch Pharm (Weinheim); 2005 Mar; 338(2-3):78-86. PubMed ID: 15736284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XXII: Bisoxazol-, bisimidazol-, bisthiazol- and oligo-1,2,4-thiadiazolimines.
    Rehse K; Martens A
    Arch Pharm (Weinheim); 1993 Jul; 326(7):399-404. PubMed ID: 8357302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thiadiazole inhibitors: a patent review.
    Dawood KM; Farghaly TA
    Expert Opin Ther Pat; 2017 Apr; 27(4):477-505. PubMed ID: 27976971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New antithrombotic 1-phthalazinamines with serotonin antagonistic properties.
    Johnsen M; Rehse K; Pertz H; Stasch JP; Bischoff E
    Arch Pharm (Weinheim); 2003 Dec; 336(12):591-7. PubMed ID: 14677153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.
    Sircar I; Steffen RP; Bobowski G; Burke SE; Newton RS; Weishaar RE; Bristol JA; Evans DB
    J Med Chem; 1989 Feb; 32(2):342-50. PubMed ID: 2536438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of 1,3,4-thiadiazole derivatives as aminopeptidase N inhibitors.
    Li SH; Li G; Huang HM; Xiong F; Mai X; Kuang BH; Liu CM; Tu GG
    Pharmazie; 2009 Feb; 64(2):67-70. PubMed ID: 19320275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and antitumor-evaluation of 1,3-selenazole-containing 1,3,4-thiadiazole derivatives.
    Zhao HC; Shi YP; Liu YM; Li CW; Xuan LN; Wang P; Zhang K; Chen BQ
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6577-9. PubMed ID: 24239016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.